OncoMatch/Clinical Trials/NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
Is NCT04972942 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Daratumumab for t-cell acute lymphoblastic leukemia.
Treatment: Daratumumab — A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Must have received: chemotherapy — re-induction therapy for relapsed T-cell LLy
relapsed T-cell LLy with complete response after re-induction therapy
Cannot have received: autologous stem cell transplant
May not have had a prior autologous or allogenic stem cell transplant
Cannot have received: allogeneic stem cell transplant
May not have had a prior autologous or allogenic stem cell transplant
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Loma Linda University Children's Hospital · Loma Linda, California
- University of California · Los Angeles, California
- University of California · San Francisco, California
- Children's Hospital Colordao · Aurora, Colorado
- Children's National Medical Center · Washington D.C., District of Columbia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04972942 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 39 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify